Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital trips.

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Schuyler County is to receive a settlement from a New Jersey pharmaceutical company and its affiliates after the county argued it contributed to the ongoing opioid ...

The pharmaceutical industry is on high alert as US President Donald Trump proposes a 200%-250% tariff on drug imports, which ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Novartis ADR NVS had its Relative Strength (RS) Rating upgraded from 66 to 71 Tuesday — a welcome improvement, but still short of the 80 or better score you prefer to see. Please watch the video at ...

Quantified, the leader in AI Roleplay for Regulated Industries, today announced it has been ranked #41 in the Artificial Intelligence & Data category on the Inc. 5000 list. This ranking underscores ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

Novartis (NVS) announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary ...

During a recent meeting, Lawrence County Attorney David Smith informed the commissioners that he needed their approval to ...